Santen Pharmaceutical Co (SZD0) AI Stock Analysis

Santen Pharmaceutical Co

(Munich:SZD0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Profitability RecoveryThe return to consistent profitability after the FY2023 loss indicates a materially stronger earnings base. Healthy gross, operating, and net margins provide capacity to fund research, product launches, market expansion, and shareholder returns over the next several quarters.

Negative Factors

Uneven Operating Cash ConversionWeak and variable conversion of earnings into operating cash can limit the predictability of internally funded growth. Although free cash flow remains positive, recurring volatility may complicate investment planning and reduce confidence that accounting profits translate consistently into liquidity.

Santen Pharmaceutical Co (SZD0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.64B
Dividend Yield: 2.05%
Average Volume (3M): ―
Price to Earnings (P/E): 15.0
Beta (1Y): 0.13
Revenue Growth: -10.36%
EPS Growth: 17.39%
Country: Germany
Employees: 3,968
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Santen Pharmaceutical Co Business Overview & Revenue Model

Company Description

Santen Pharmaceutical Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, with operations spanning Japan and international markets. The company maintains a s...

Santen Pharmaceutical Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:SZD0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LLY	81Outperform	$1.33T	45.89	83.65%	0.47%	45.51%	50.48%
ABBV	72Outperform	$521.11B	83.08	-223.75%	2.35%	10.68%	―
NVS	72Outperform	$297.25B	31.19	24.24%	2.95%	1.64%	-28.72%
PFE	65Neutral	$173.95B	40.33	4.89%	5.64%	-0.21%	-59.71%
MRK	63Neutral	$368.89B	152.57	5.10%	2.27%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:SZD0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:SZD0	Santen Pharmaceutical	10.10	1.75	21.00%
LLY	Eli Lilly And Company	1417.54	526.63	59.11%
MRK	Merck & Company	149.52	69.38	86.58%
NVS	Novartis AG	160.79	39.31	32.36%
PFE	Pfizer Inc	30.52	7.48	32.45%
ABBV	Abbvie	294.89	89.09	43.29%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Santen Pharmaceutical Co AI Stock Analysis